A Contract Development and Manufacturing Organization (CDMO) that specializes in sterile injectables focuses on the development and manufacturing of injectable drugs in a sterile environment. These organizations typically offer services ranging from formulation development to final sterile fill and finish. They adhere to strict regulatory standards to ensure the safety, efficacy, and quality of the injectable products they produce. Sterile injectables are crucial for various medical applications, including intravenous, intramuscular, and subcutaneous administration of medications. A CDMO specializing in this area plays a vital role in bringing these essential pharmaceutical products to market.
The global Sterile Injectable CDMO market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.
The 鈥淪terile Injectable CDMO Industry Forecast鈥� looks at past sales and reviews total world Sterile Injectable CDMO sales in 2022, providing a comprehensive analysis by region and market sector of projected Sterile Injectable CDMO sales for 2023 through 2029. With Sterile Injectable CDMO sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Sterile Injectable CDMO industry.
This Insight Report provides a comprehensive analysis of the global Sterile Injectable CDMO landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Sterile Injectable CDMO portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Sterile Injectable CDMO market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Sterile Injectable CDMO and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Sterile Injectable CDMO.
United States market for Sterile Injectable CDMO is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for Sterile Injectable CDMO is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for Sterile Injectable CDMO is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key Sterile Injectable CDMO players cover Abbvie, Famar, Polfa Tarchomin, Pfizer, Quotient Sciences, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of Sterile Injectable CDMO market by product type, application, key players and key regions and countries.
Segmentation by Type:
Preclinical Manufacturing
Clinical Manufacturing
Commercial Manufacturing
Segmentation by Application:
Pharmaceutical Company
Research Institute
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
Segmentation by Type:
Preclinical Manufacturing
Clinical Manufacturing
Commercial Manufacturing
Segmentation by Application:
Pharmaceutical Company
Research Institute
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Abbvie
Famar
Polfa Tarchomin
Pfizer
Quotient Sciences
Temad Co.
Tianjin Hankang Pharmaceutical Biotechnology
Fareva
Sharp
Astral SteriTech
Evonik
Aurigene Pharmaceutical Services
Prague Scientific
Ethypharm
TriRx Pharmaceutical Services
Biophrama Group
Gensenta Pharmaceuticals
BioTechnique
Mithra CDMo
S.C. Rompharm Company SRL
Flagship Biotech International Pvt. Ltd
Curida AS
BirgiMefar Group
Brooks Laboratories Limited
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Sterile Injectable CDMO Market Size 2019-2030
2.1.2 Sterile Injectable CDMO Market Size CAGR by Region (2019 VS 2023 VS 2030)
2.1.3 World Current & Future Analysis for Sterile Injectable CDMO by Country/Region, 2019, 2023 & 2030
2.2 Sterile Injectable CDMO Segment by Type
2.2.1 Preclinical Manufacturing
2.2.2 Clinical Manufacturing
2.2.3 Commercial Manufacturing
2.3 Sterile Injectable CDMO Market Size by Type
2.3.1 Sterile Injectable CDMO Market Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global Sterile Injectable CDMO Market Size Market Share by Type (2019-2024)
2.4 Sterile Injectable CDMO Segment by Application
2.4.1 Pharmaceutical Company
2.4.2 Research Institute
2.4.3 Other
2.5 Sterile Injectable CDMO Market Size by Application
2.5.1 Sterile Injectable CDMO Market Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global Sterile Injectable CDMO Market Size Market Share by Application (2019-2024)
3 Sterile Injectable CDMO Market Size by Player
3.1 Sterile Injectable CDMO Market Size Market Share by Player
3.1.1 Global Sterile Injectable CDMO Revenue by Player (2019-2024)
3.1.2 Global Sterile Injectable CDMO Revenue Market Share by Player (2019-2024)
3.2 Global Sterile Injectable CDMO Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Sterile Injectable CDMO by Region
4.1 Sterile Injectable CDMO Market Size by Region (2019-2024)
4.2 Global Sterile Injectable CDMO Annual Revenue by Country/Region (2019-2024)
4.3 Americas Sterile Injectable CDMO Market Size Growth (2019-2024)
4.4 APAC Sterile Injectable CDMO Market Size Growth (2019-2024)
4.5 Europe Sterile Injectable CDMO Market Size Growth (2019-2024)
4.6 Middle East & Africa Sterile Injectable CDMO Market Size Growth (2019-2024)
5 Americas
5.1 Americas Sterile Injectable CDMO Market Size by Country (2019-2024)
5.2 Americas Sterile Injectable CDMO Market Size by Type (2019-2024)
5.3 Americas Sterile Injectable CDMO Market Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Sterile Injectable CDMO Market Size by Region (2019-2024)
6.2 APAC Sterile Injectable CDMO Market Size by Type (2019-2024)
6.3 APAC Sterile Injectable CDMO Market Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Sterile Injectable CDMO Market Size by Country (2019-2024)
7.2 Europe Sterile Injectable CDMO Market Size by Type (2019-2024)
7.3 Europe Sterile Injectable CDMO Market Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Sterile Injectable CDMO by Region (2019-2024)
8.2 Middle East & Africa Sterile Injectable CDMO Market Size by Type (2019-2024)
8.3 Middle East & Africa Sterile Injectable CDMO Market Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Sterile Injectable CDMO Market Forecast
10.1 Global Sterile Injectable CDMO Forecast by Region (2025-2030)
10.1.1 Global Sterile Injectable CDMO Forecast by Region (2025-2030)
10.1.2 Americas Sterile Injectable CDMO Forecast
10.1.3 APAC Sterile Injectable CDMO Forecast
10.1.4 Europe Sterile Injectable CDMO Forecast
10.1.5 Middle East & Africa Sterile Injectable CDMO Forecast
10.2 Americas Sterile Injectable CDMO Forecast by Country (2025-2030)
10.2.1 United States Market Sterile Injectable CDMO Forecast
10.2.2 Canada Market Sterile Injectable CDMO Forecast
10.2.3 Mexico Market Sterile Injectable CDMO Forecast
10.2.4 Brazil Market Sterile Injectable CDMO Forecast
10.3 APAC Sterile Injectable CDMO Forecast by Region (2025-2030)
10.3.1 China Sterile Injectable CDMO Market Forecast
10.3.2 Japan Market Sterile Injectable CDMO Forecast
10.3.3 Korea Market Sterile Injectable CDMO Forecast
10.3.4 Southeast Asia Market Sterile Injectable CDMO Forecast
10.3.5 India Market Sterile Injectable CDMO Forecast
10.3.6 Australia Market Sterile Injectable CDMO Forecast
10.4 Europe Sterile Injectable CDMO Forecast by Country (2025-2030)
10.4.1 Germany Market Sterile Injectable CDMO Forecast
10.4.2 France Market Sterile Injectable CDMO Forecast
10.4.3 UK Market Sterile Injectable CDMO Forecast
10.4.4 Italy Market Sterile Injectable CDMO Forecast
10.4.5 Russia Market Sterile Injectable CDMO Forecast
10.5 Middle East & Africa Sterile Injectable CDMO Forecast by Region (2025-2030)
10.5.1 Egypt Market Sterile Injectable CDMO Forecast
10.5.2 South Africa Market Sterile Injectable CDMO Forecast
10.5.3 Israel Market Sterile Injectable CDMO Forecast
10.5.4 Turkey Market Sterile Injectable CDMO Forecast
10.6 Global Sterile Injectable CDMO Forecast by Type (2025-2030)
10.7 Global Sterile Injectable CDMO Forecast by Application (2025-2030)
10.7.1 GCC Countries Market Sterile Injectable CDMO Forecast
11 Key Players Analysis
11.1 Abbvie
11.1.1 Abbvie Company Information
11.1.2 Abbvie Sterile Injectable CDMO Product Offered
11.1.3 Abbvie Sterile Injectable CDMO Revenue, Gross Margin and Market Share (2019-2024)
11.1.4 Abbvie Main Business Overview
11.1.5 Abbvie Latest Developments
11.2 Famar
11.2.1 Famar Company Information
11.2.2 Famar Sterile Injectable CDMO Product Offered
11.2.3 Famar Sterile Injectable CDMO Revenue, Gross Margin and Market Share (2019-2024)
11.2.4 Famar Main Business Overview
11.2.5 Famar Latest Developments
11.3 Polfa Tarchomin
11.3.1 Polfa Tarchomin Company Information
11.3.2 Polfa Tarchomin Sterile Injectable CDMO Product Offered
11.3.3 Polfa Tarchomin Sterile Injectable CDMO Revenue, Gross Margin and Market Share (2019-2024)
11.3.4 Polfa Tarchomin Main Business Overview
11.3.5 Polfa Tarchomin Latest Developments
11.4 Pfizer
11.4.1 Pfizer Company Information
11.4.2 Pfizer Sterile Injectable CDMO Product Offered
11.4.3 Pfizer Sterile Injectable CDMO Revenue, Gross Margin and Market Share (2019-2024)
11.4.4 Pfizer Main Business Overview
11.4.5 Pfizer Latest Developments
11.5 Quotient Sciences
11.5.1 Quotient Sciences Company Information
11.5.2 Quotient Sciences Sterile Injectable CDMO Product Offered
11.5.3 Quotient Sciences Sterile Injectable CDMO Revenue, Gross Margin and Market Share (2019-2024)
11.5.4 Quotient Sciences Main Business Overview
11.5.5 Quotient Sciences Latest Developments
11.6 Temad Co.
11.6.1 Temad Co. Company Information
11.6.2 Temad Co. Sterile Injectable CDMO Product Offered
11.6.3 Temad Co. Sterile Injectable CDMO Revenue, Gross Margin and Market Share (2019-2024)
11.6.4 Temad Co. Main Business Overview
11.6.5 Temad Co. Latest Developments
11.7 Tianjin Hankang Pharmaceutical Biotechnology
11.7.1 Tianjin Hankang Pharmaceutical Biotechnology Company Information
11.7.2 Tianjin Hankang Pharmaceutical Biotechnology Sterile Injectable CDMO Product Offered
11.7.3 Tianjin Hankang Pharmaceutical Biotechnology Sterile Injectable CDMO Revenue, Gross Margin and Market Share (2019-2024)
11.7.4 Tianjin Hankang Pharmaceutical Biotechnology Main Business Overview
11.7.5 Tianjin Hankang Pharmaceutical Biotechnology Latest Developments
11.8 Fareva
11.8.1 Fareva Company Information
11.8.2 Fareva Sterile Injectable CDMO Product Offered
11.8.3 Fareva Sterile Injectable CDMO Revenue, Gross Margin and Market Share (2019-2024)
11.8.4 Fareva Main Business Overview
11.8.5 Fareva Latest Developments
11.9 Sharp
11.9.1 Sharp Company Information
11.9.2 Sharp Sterile Injectable CDMO Product Offered
11.9.3 Sharp Sterile Injectable CDMO Revenue, Gross Margin and Market Share (2019-2024)
11.9.4 Sharp Main Business Overview
11.9.5 Sharp Latest Developments
11.10 Astral SteriTech
11.10.1 Astral SteriTech Company Information
11.10.2 Astral SteriTech Sterile Injectable CDMO Product Offered
11.10.3 Astral SteriTech Sterile Injectable CDMO Revenue, Gross Margin and Market Share (2019-2024)
11.10.4 Astral SteriTech Main Business Overview
11.10.5 Astral SteriTech Latest Developments
11.11 Evonik
11.11.1 Evonik Company Information
11.11.2 Evonik Sterile Injectable CDMO Product Offered
11.11.3 Evonik Sterile Injectable CDMO Revenue, Gross Margin and Market Share (2019-2024)
11.11.4 Evonik Main Business Overview
11.11.5 Evonik Latest Developments
11.12 Aurigene Pharmaceutical Services
11.12.1 Aurigene Pharmaceutical Services Company Information
11.12.2 Aurigene Pharmaceutical Services Sterile Injectable CDMO Product Offered
11.12.3 Aurigene Pharmaceutical Services Sterile Injectable CDMO Revenue, Gross Margin and Market Share (2019-2024)
11.12.4 Aurigene Pharmaceutical Services Main Business Overview
11.12.5 Aurigene Pharmaceutical Services Latest Developments
11.13 Prague Scientific
11.13.1 Prague Scientific Company Information
11.13.2 Prague Scientific Sterile Injectable CDMO Product Offered
11.13.3 Prague Scientific Sterile Injectable CDMO Revenue, Gross Margin and Market Share (2019-2024)
11.13.4 Prague Scientific Main Business Overview
11.13.5 Prague Scientific Latest Developments
11.14 Ethypharm
11.14.1 Ethypharm Company Information
11.14.2 Ethypharm Sterile Injectable CDMO Product Offered
11.14.3 Ethypharm Sterile Injectable CDMO Revenue, Gross Margin and Market Share (2019-2024)
11.14.4 Ethypharm Main Business Overview
11.14.5 Ethypharm Latest Developments
11.15 TriRx Pharmaceutical Services
11.15.1 TriRx Pharmaceutical Services Company Information
11.15.2 TriRx Pharmaceutical Services Sterile Injectable CDMO Product Offered
11.15.3 TriRx Pharmaceutical Services Sterile Injectable CDMO Revenue, Gross Margin and Market Share (2019-2024)
11.15.4 TriRx Pharmaceutical Services Main Business Overview
11.15.5 TriRx Pharmaceutical Services Latest Developments
11.16 Biophrama Group
11.16.1 Biophrama Group Company Information
11.16.2 Biophrama Group Sterile Injectable CDMO Product Offered
11.16.3 Biophrama Group Sterile Injectable CDMO Revenue, Gross Margin and Market Share (2019-2024)
11.16.4 Biophrama Group Main Business Overview
11.16.5 Biophrama Group Latest Developments
11.17 Gensenta Pharmaceuticals
11.17.1 Gensenta Pharmaceuticals Company Information
11.17.2 Gensenta Pharmaceuticals Sterile Injectable CDMO Product Offered
11.17.3 Gensenta Pharmaceuticals Sterile Injectable CDMO Revenue, Gross Margin and Market Share (2019-2024)
11.17.4 Gensenta Pharmaceuticals Main Business Overview
11.17.5 Gensenta Pharmaceuticals Latest Developments
11.18 BioTechnique
11.18.1 BioTechnique Company Information
11.18.2 BioTechnique Sterile Injectable CDMO Product Offered
11.18.3 BioTechnique Sterile Injectable CDMO Revenue, Gross Margin and Market Share (2019-2024)
11.18.4 BioTechnique Main Business Overview
11.18.5 BioTechnique Latest Developments
11.19 Mithra CDMo
11.19.1 Mithra CDMo Company Information
11.19.2 Mithra CDMo Sterile Injectable CDMO Product Offered
11.19.3 Mithra CDMo Sterile Injectable CDMO Revenue, Gross Margin and Market Share (2019-2024)
11.19.4 Mithra CDMo Main Business Overview
11.19.5 Mithra CDMo Latest Developments
11.20 S.C. Rompharm Company SRL
11.20.1 S.C. Rompharm Company SRL Company Information
11.20.2 S.C. Rompharm Company SRL Sterile Injectable CDMO Product Offered
11.20.3 S.C. Rompharm Company SRL Sterile Injectable CDMO Revenue, Gross Margin and Market Share (2019-2024)
11.20.4 S.C. Rompharm Company SRL Main Business Overview
11.20.5 S.C. Rompharm Company SRL Latest Developments
11.21 Flagship Biotech International Pvt. Ltd
11.21.1 Flagship Biotech International Pvt. Ltd Company Information
11.21.2 Flagship Biotech International Pvt. Ltd Sterile Injectable CDMO Product Offered
11.21.3 Flagship Biotech International Pvt. Ltd Sterile Injectable CDMO Revenue, Gross Margin and Market Share (2019-2024)
11.21.4 Flagship Biotech International Pvt. Ltd Main Business Overview
11.21.5 Flagship Biotech International Pvt. Ltd Latest Developments
11.22 Curida AS
11.22.1 Curida AS Company Information
11.22.2 Curida AS Sterile Injectable CDMO Product Offered
11.22.3 Curida AS Sterile Injectable CDMO Revenue, Gross Margin and Market Share (2019-2024)
11.22.4 Curida AS Main Business Overview
11.22.5 Curida AS Latest Developments
11.23 BirgiMefar Group
11.23.1 BirgiMefar Group Company Information
11.23.2 BirgiMefar Group Sterile Injectable CDMO Product Offered
11.23.3 BirgiMefar Group Sterile Injectable CDMO Revenue, Gross Margin and Market Share (2019-2024)
11.23.4 BirgiMefar Group Main Business Overview
11.23.5 BirgiMefar Group Latest Developments
11.24 Brooks Laboratories Limited
11.24.1 Brooks Laboratories Limited Company Information
11.24.2 Brooks Laboratories Limited Sterile Injectable CDMO Product Offered
11.24.3 Brooks Laboratories Limited Sterile Injectable CDMO Revenue, Gross Margin and Market Share (2019-2024)
11.24.4 Brooks Laboratories Limited Main Business Overview
11.24.5 Brooks Laboratories Limited Latest Developments
12 Research Findings and Conclusion
听
听
*If Applicable.